These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 21264447

  • 1. Factor VIII delivered by haematopoietic stem cell-derived B cells corrects the phenotype of haemophilia A mice.
    Ramezani A, Zweier-Renn LA, Hawley RG.
    Thromb Haemost; 2011 Apr; 105(4):676-87. PubMed ID: 21264447
    [Abstract] [Full Text] [Related]

  • 2. Lentivirus-mediated platelet gene therapy of murine hemophilia A with pre-existing anti-factor VIII immunity.
    Kuether EL, Schroeder JA, Fahs SA, Cooley BC, Chen Y, Montgomery RR, Wilcox DA, Shi Q.
    J Thromb Haemost; 2012 Aug; 10(8):1570-80. PubMed ID: 22632092
    [Abstract] [Full Text] [Related]

  • 3. Lentivirus-mediated platelet-derived factor VIII gene therapy in murine haemophilia A.
    Shi Q, Wilcox DA, Fahs SA, Fang J, Johnson BD, DU LM, Desai D, Montgomery RR.
    J Thromb Haemost; 2007 Feb; 5(2):352-61. PubMed ID: 17269937
    [Abstract] [Full Text] [Related]

  • 4. Correction of murine hemophilia A by hematopoietic stem cell gene therapy.
    Moayeri M, Hawley TS, Hawley RG.
    Mol Ther; 2005 Dec; 12(6):1034-42. PubMed ID: 16226058
    [Abstract] [Full Text] [Related]

  • 5. Preclinical Development of a Hematopoietic Stem and Progenitor Cell Bioengineered Factor VIII Lentiviral Vector Gene Therapy for Hemophilia A.
    Doering CB, Denning G, Shields JE, Fine EJ, Parker ET, Srivastava A, Lollar P, Spencer HT.
    Hum Gene Ther; 2018 Oct; 29(10):1183-1201. PubMed ID: 30160169
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Phenotypic correction of a mouse model of hemophilia A using AAV2 vectors encoding the heavy and light chains of FVIII.
    Scallan CD, Liu T, Parker AE, Patarroyo-White SL, Chen H, Jiang H, Vargas J, Nagy D, Powell SK, Wright JF, Sarkar R, Kazazian HH, McClelland A, Couto LB.
    Blood; 2003 Dec 01; 102(12):3919-26. PubMed ID: 12893764
    [Abstract] [Full Text] [Related]

  • 14. Immune tolerance induced by platelet-targeted factor VIII gene therapy in hemophilia A mice is CD4 T cell mediated.
    Chen Y, Luo X, Schroeder JA, Chen J, Baumgartner CK, Hu J, Shi Q.
    J Thromb Haemost; 2017 Oct 01; 15(10):1994-2004. PubMed ID: 28799202
    [Abstract] [Full Text] [Related]

  • 15. The impact of GPIbα on platelet-targeted FVIII gene therapy in hemophilia A mice with pre-existing anti-FVIII immunity.
    Chen J, Schroeder JA, Luo X, Montgomery RR, Shi Q.
    J Thromb Haemost; 2019 Mar 01; 17(3):449-459. PubMed ID: 30609275
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Ex vivo gene therapy for hemophilia A that enhances safe delivery and sustained in vivo factor VIII expression from lentivirally engineered endothelial progenitors.
    Matsui H, Shibata M, Brown B, Labelle A, Hegadorn C, Andrews C, Hebbel RP, Galipeau J, Hough C, Lillicrap D.
    Stem Cells; 2007 Oct 01; 25(10):2660-9. PubMed ID: 17615271
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.